Vertex Pharmaceuticals, Boston, MA, USA.
Health Economics and Outcomes Research, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, 02210, USA.
Health Qual Life Outcomes. 2024 Jul 11;22(1):54. doi: 10.1186/s12955-024-02265-8.
Individuals with transfusion-dependent β-thalassemia (TDT) experience symptoms and functional impacts that reduce their health-related quality of life. However, EQ-5D-derived health utility index scores in TDT often indicate good HRQoL, suggesting the EQ-5D may not adequately capture the impact of TDT. This study explored the disease and treatment burden of TDT and examined the appropriateness of the EQ-5D-5L descriptive system (DS) in measuring HRQoL in TDT.
Adults with TDT in the United Kingdom, United States, and France completed a background questionnaire and EQ-5D-5L DS, followed by 60-minute semi-structured interviews on symptoms and HRQoL impacts of TDT (concept elicitation) and appropriateness of EQ-5D-5L DS (cognitive debrief). Transcribed interviews were analyzed using thematic and content analyses. The relationship between TDT symptoms and impacts were summarized in a conceptual model. EQ-5D-5L DS was mapped to concepts identified in the qualitative data to assess its capture of HRQoL concepts. Participants' EQ-5D-5L DS scores were compared to their qualitative descriptions for each dimension to assess their concordance.
Thirty participants in the United States (n = 14 [46.7%]), United Kingdom. (n = 12 [40.0%]), and France (n = 4 [13.3%]) completed the study (73.3% female; mean age = 28.4 years [standard deviation (SD) = 5.1]; mean annual red blood cell transfusion [RBCT] frequency = 18.4 [SD = 7.6]). Participants reported TDT symptoms and impacts on HRQoL, all fluctuating across the RBCT cycle. EQ-5D-5L DS did not fully capture 11 of 16 (68.8%) HRQoL concepts reported. Most participants (n = 20/27 [74.1%]) reported that EQ-5D-5L DS did not capture important aspects of living with TDT, and 42.9% (n = 12/28) reported negative/neutral overall impressions of EQ-5D-5L DS. The highest degree of discordance between participants' qualitative data and EQ-5D-5L DS dimension scores was observed with mobility (42.3%) and self-care (34.6%), where the qualitative descriptions relating to these dimensions were worse than their quantitative scores.
Current findings suggest that EQ-5D-5L DS lacks content validity and the derived health utility index score may not fully represent the burden of disease in TDT.
依赖输血的β-地中海贫血症(TDT)患者会出现症状和功能障碍,从而降低其健康相关生活质量。然而,TDT 的 EQ-5D 衍生健康效用指数评分通常表明 HRQoL 良好,这表明 EQ-5D 可能无法充分捕捉 TDT 的影响。本研究旨在探讨 TDT 的疾病和治疗负担,并考察 EQ-5D-5L 描述系统(DS)在衡量 TDT 的 HRQoL 方面的适宜性。
英国、美国和法国的 TDT 成年患者完成背景问卷和 EQ-5D-5L DS,然后进行时长为 60 分钟的半结构化访谈,内容涉及 TDT 症状和 HRQoL 影响(概念发掘)以及 EQ-5D-5L DS 的适宜性(认知审查)。对转录后的访谈采用主题和内容分析法进行分析。将 TDT 症状与影响之间的关系总结为一个概念模型。将 EQ-5D-5L DS 映射到定性数据中确定的概念,以评估其对 HRQoL 概念的捕捉程度。将患者的 EQ-5D-5L DS 评分与每个维度的定性描述进行比较,以评估其一致性。
共有 30 名参与者(美国 14 名[46.7%]、英国 12 名[40.0%]和法国 4 名[13.3%])完成了该研究(女性占 73.3%;平均年龄 28.4 岁[标准差 5.1];平均每年接受红细胞输血频率为 18.4[标准差 7.6])。参与者报告了 TDT 症状和对 HRQoL 的影响,所有症状均在 RBC 输血周期中波动。EQ-5D-5L DS 未能完全捕捉到 16 个 HRQoL 概念中的 11 个(68.8%)。大多数参与者(n=20/27[74.1%])表示 EQ-5D-5L DS 未能捕捉到 TDT 生活的重要方面,42.9%(n=12/28)对 EQ-5D-5L DS 总体印象为负面/中性。参与者的定性数据与 EQ-5D-5L DS 维度评分之间的最大程度不一致发生在移动性(42.3%)和自我护理(34.6%)方面,与这些维度相关的定性描述比定量评分更差。
目前的研究结果表明,EQ-5D-5L DS 缺乏内容有效性,衍生的健康效用指数评分可能无法充分代表 TDT 的疾病负担。